About Vaxart Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform.

Vaxart believes that its proprietary pill vaccine delivery platform is suitable to deliver recombinant vaccines, positioning the company to develop oral versions of currently marketed vaccines and ...

Vaxart believes that its proprietary pill vaccine delivery platform is suitable to deliver recombinant vaccines, positioning the company to develop oral versions of currently marketed vaccines and ...

Vaxart's (VXRT) shares soar 37% after positive early trial results for its oral norovirus vaccine. Read more here.

SOUTH SAN FRANCISCO, Calif., May 28, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) (the “Company” OR “Vaxart”) today answers additional frequently asked stockholder questions it has ...

Vaxart (NASDAQ: VXRT) shares rose in post-market trading on Wednesday after the company announced the publication of complete data from a Phase 2 trial for its oral pill norovirus vaccine ...

Vaxart previously published positive, complete data from a Phase 1b trial of its first-generation norovirus vaccine candidate in elderly adults, a patient population that often has age-related ...

Vaxart appointed Jeroen Grasman as its chief financial officer, effective May 19. Grasman will succeed Phillip Lee, who is resigning from the top finance position for personal reasons, the ...

Vaxart (NASDAQ:VXRT – Get Free Report) and NKGen Biotech (NYSE:NKGN – Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two ...

Vaxart’s development programs currently include pill vaccines designed to protect against coronavirus, norovirus and influenza, as well as a therapeutic vaccine for human papillomavirus (HPV ...